Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide in sickle cell disease patients
IRCT20180603039959N4Phase 2Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of thalidomide and aspirin in sickle cell anemia (SCA) (2 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoints: Average Visual Analog Scale for Pain score, Interleukin-6 concentration and 3 more. Started Nov 2024; status: completed.
02
Drugs
thalidomideaspirin
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on IRCT20180603039959N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180603039959N4.